placebo group

Women in the placebo group, not on an aromatase inhibitor, maintained BMD at the spine, but had a significant 1. 2% loss at the total hip.

Even more disappointing was the small difference in weight loss between the placebo group and the group that received sibutramine.

patients who supplemented with pycnogenol ? also had increased antioxidant levels compared to the placebo group.

the most common adverse event was the symptoms of digestive tract which differed much from that in the placebo group (P05).

After three weeks, 60 percent of the placebo group reported relief from symptoms, compared to 35 percent who'd received no treatment at all.

So caffeine wipes out the false memories! The placebo group was indistinguishable from the night-wake group in the first experiment.

Blood pressure in both groups was managed according to a standard protocol. The placebo group received matching placebos .

By contrast, just two of the eight patients in the placebo group showed a substantial improvement in symptoms.

More increases in the creatinine concentration were reported as serious adverse events in the dronedarone group than in the placebo group.

Safety tests revealed that "no adverse event occurred more frequently in the vaccinated than in the placebo group" , say the researchers.

It's worth noting that the varenicline takers also smoked far fewer cigarettes than the placebo group during the 14-hour the experiment.

Experiment finds caffeinedrinkers more influenced by a persuasive message than a placebo group.

After eight months, the diazoxide group outperformed the placebo group on both learning and memory.

Yet unexpectedly, those in the placebo group improved the most, significantly more so than those on medication.

Compared with the placebo group, the colesevelam group had a 12. 8% decrease in low-density lipoprotein cholesterol concentration (P . 001).

Only six percent of the zinc-treated group achieved complete taste recovery, compared to 18 percent in the placebo group.

Instead, the cumulative incidence of type 2 diabetes was statistically significantly higher in the selenium group than in the placebo group.

The soy group received 200mg of soy isoflavone tablets daily for two years, while the women in the placebo group were given dummy pills.

At the end of the two-year trial, there were 134 infections in the Carraguard group and 151 in the placebo group.

Drug-related toxic effects caused discontinuation of treatment in 5 percent of the pemetrexed group and 4 percent of the placebo group.

Over the course of the trial, 74 people from the placebo group and 51 in the vaccine group became infected.

In the final 12 weeks, all patients in the placebo group received follow-upand could be actively treated if their depression relapsed.

Maloney says the reduction in the placebo group is a reflection of thetypical placebo response.

In contrast, improvements in the placebo group diminished oer time and ultimately dropped below baseline levels.

Treatment duration was a median of 23 weeks in the sorafenib group and 19 weeks in the placebo group.

In both studies, patients assigned to tolvaptan had higher serum sodium concentrations at day 4 and day 30 than those in the placebo group.

If the placebo group happen to have more and more people are at high risk of AIDS, then the meaning of statistical data will be compromised.

In the placebo group, 112 patients were randomly assigned toplacebo treatment in a double-blind manner for the first 12weeks.

Results At 1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group.

Insulin sensitivity in the liver improved by 48 percent in the pioglitazone group, compared to 14 percent in the placebo group.

Dropout rate due to adverse events was 11% in the PIR group and 0% in the placebo group.

Only 1 new fingertip ulcer was reported in the tadalafil group, compared with 13 new ulcers in the placebo group.

More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.

while in the placebo group of 8198 people, there are 74 people infected - after vaccination, AIDS infection rate reduced .

The study didn't have a placebo group for comparison, generally considered necessary for a conclusive result.

In their intent-to-treat analysis, clinical cure rates were 81. 7% in the amoxicillin arm and 84. 0% in the placebo group.

After 12 months, children who took the cavity-fighting mints had 61. 7 percent fewer cavities than the placebo group.

Caveat: While the patients receiving only standard care were a control group, the study didn't use a placebo group.

The placebo group only lost an average of 2 lbs.

The number of deaths at six months was 104 (14. 3 Percent) in the tezosentan group and 101 (14. 3 Percent) in the placebo group.

74 people in the placebo group became infected during the study.

There were 121 (15. 7%) serious adverse events in the nadroparin goup and 67 (17. 6%) serious adverse events in the placebo group.

Median overall survival was 46 weeks in the sorafenib group and 34 weeks in the placebo group (HR 0. 69, P =. 00058).

Results: A total of 88 women, 47 receiving active treatment and 41 in the placebo group, completed the study.

Increases in blood pressure were considerably more frequent in the placebo group (12. 6% and 11. 4%; P 0. 001).

Participants taking 1, 200 Mg of calcium daily found their symptoms diminished by 48 percent, compared with 30 percent in the placebo group